ADXN
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
24.48M
GET INTRADAY SIGNALS
ADXN Trading results, last 6 months
AI Robots NameP/LEntry Price, $Profit, $/%
45 days until earnings call
+Compare
ADXN
Stock ticker:
NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
24.48M

ADXN Price Prediction, Addex Therapeutics Ltd AI Recommendations

Stock market charts, price targets, analyst ratings and a financial calendar

GET INTRADAY SIGNALS
ADXN Trading results, last 6 months
AI Robots NameP/LEntry Price, $Profit, $/%
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
AI
A.I.Advisor
a Summary for AAPL with price predictions
12:00 AM EDT Mar 23, 2023

Momentum Indicator for ADXN turns negative, indicating new downward trend

ADXN saw its Momentum Indicator move below the 0 level on March 03, 2023. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 87 similar instances where the indicator turned negative. In 79 of the 87 cases, the stock moved further down in the following days. The odds of a decline are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for ADXN turned negative on March 03, 2023. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 29 similar instances when the indicator turned negative. In of the 29 cases the stock turned lower in the days that followed. This puts the odds of success at .

ADXN moved below its 50-day moving average on March 15, 2023 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for ADXN crossed bearishly below the 50-day moving average on March 17, 2023. This indicates that the trend has shifted lower and could be considered a sell signal. In of 9 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ADXN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ADXN's RSI Indicator exited the oversold zone, of 18 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 47 cases where ADXN's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ADXN advanced for three days, in of 104 cases, the price rose further within the following month. The odds of a continued upward trend are .

ADXN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 32 cases where ADXN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.674) is normal, around the industry mean (21.708). P/E Ratio (0.000) is within average values for comparable stocks, (125.534). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.749). Dividend Yield (0.000) settles around the average of (0.028) among similar stocks. P/S Ratio (5.949) is also within normal values, averaging (303.071).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ADXN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ADXN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

AI
A.I. Advisor
published Earnings

ADXN is expected to report earnings to fall 42.67% to -5 cents per share on March 23

Addex Therapeutics Ltd ADXN Stock Earnings Reports
Q4'22
Est.
$-0.05
Q3'22
Est.
$-0.09
Q2'22
Missed
by $1.05
Q1'22
Missed
by $0.40
Q4'21
Missed
by $0.19
The last earnings report on November 11 showed earnings per share of -9 cents, meeting the estimate of -9 cents. With 2.34K shares outstanding, the current market capitalization sits at 24.48M.
AI
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Novavax (NASDAQ:NVAX), Inovio Pharmaceuticals (NASDAQ:INO).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 1.96B. The market cap for tickers in the group ranges from 160 to 331.75B. NONOF holds the highest valuation in this group at 331.75B. The lowest valued company is CDXI at 160.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -0%. For the same Industry, the average monthly price growth was -8%, and the average quarterly price growth was -0%. CALC experienced the highest price growth at 1,040%, while MMIRF experienced the biggest fall at -92%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 8%. For the same stocks of the Industry, the average monthly volume growth was -33% and the average quarterly volume growth was -64%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 85
Price Growth Rating: 62
SMR Rating: 92
Profit Risk Rating: 94
Seasonality Score: -2 (-100 ... +100)
AI
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
AI
A.I.Advisor
published price charts
AI
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
Chemin des Aulx 12
Phone
+41 228841555
Employees
28
Web
http://www.addextherapeutics.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
NCMI0.130.01
+6.13%
National CineMedia
ASTI0.430.02
+4.15%
Ascent Solar Technologies
TCOM37.390.20
+0.54%
Trip.com Group Limited
GDOT16.13-0.14
-0.86%
Green Dot Corp
TIGO18.14-0.18
-0.98%
Millicom International Cellular SA

ADXN and

Correlation & Price change

A.I.dvisor tells us that ADXN and ENTX have been poorly correlated (+20% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ADXN and ENTX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ADXN
1D Price
Change %
ADXN100%
-11.67%
ENTX - ADXN
20%
Poorly correlated
+0.95%
BRTX - ADXN
13%
Poorly correlated
-2.16%
ZVRA - ADXN
7%
Poorly correlated
-0.09%
OLMA - ADXN
7%
Poorly correlated
+3.52%
PHAR - ADXN
6%
Poorly correlated
-1.14%
More